Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Bactiguard, Audiocast, Q3'26

By Inderes10/22/2026, 9:00 AM
Bactiguard

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Christine Lind
00:01 - 07:44

Thank you, operator, and a warm welcome to Bactiguard's third quarter presentation for 2026. I am joining you today from Boston. Following a couple of days at the AdvaMed MedTech Trade Association conference, where medtech leaders come together. With me on the call is our CFO, Patrick Bach. I will take you through the quarter's strategic highlights, then hand over to Patrick for a closer look at the numbers before we open the line for your questions. Today's title, Accelerating Performance, validates our partnership model and captures exactly where we landed: a very strong third quarter, following a solid second. With growth in our licensed business flowing straight through to earnings and cash flow. So let's dive straight into the quarter. Let's start with some high-level numbers. We are very pleased to report third quarter net sales growth, excluding currency, of 24%, with total revenue of 58 MSEK, up from 48 MSEK a year ago. License revenues grew 40%, excluding currency, driven mainly by the BD partnership, where we saw the strongest growth in a decade. Adjusted EBITDA came in at 20 MSEK, corresponding to a margin of 34%. It is a clear demonstration of the operating leverage of the license business, with top-line growth flowing through to earnings and cash flow. Strategically, it was a quarter of real progress. BD is performing strongly across both established and newly launched markets. Market-based revenues from Zimmer Biomet are gaining momentum, and we made meaningful headway in our partner dialogues, with the strongest engagement in orthopedics. Let me take these one at a time. Let's turn to the BD partnership, which was a key contributor to the performance this quarter. Revenues from BD grew 30%, excluding currency, and the growth in the partnership is the strongest we have seen in a decade, coming both from contract manufacturing as well as royalties on market sales. What makes this particularly encouraging is understanding why this is happening. The long-standing markets keep performing well, and the markets launched over the past year, such as the Nordics, Poland, and parts of the Middle East, are now generating increasing demand. That reflects the cumulative impact of our cooperation and development efforts with BD. The regulatory approvals, the technology training across the regions, and the continued commercialization and market development activities in Europe. Increasing volumes in these newer markets validate the work behind those market transitions, and they support our confidence in the long-term expansion of the partnership. It's also worth remembering the foundation. This is a partnership that goes back to the early 1990s, with more than 245 million Bactiguard coated Foley catheters to date, and with BD having the exclusive global rights outside of China since late 2023. We renewed this agreement for the long term as recently as earlier this year, and there is still plenty of opportunity for us to grow together. Now to Zimmer Biomet. Under the amended agreement signed late 2025, our royalties are now more closely tied to underlying market performance. This quarter, we saw that start to come through, and in addition to fixed fees, we had double-digit growth in royalties from in-market product sales. Our partnership with a global leader in orthopedics has clear long-term potential as the use of and demand for Bactiguard-coated implants grows. We also continue to execute on our regulatory programs and on our scientific publication and visibility strategy. In September, we presented new data at two leading conferences, including a joint publication with Zimmer Biomet comparing silver-containing surface technologies, which shows that silver is not the same as silver, and the differentiation of our noble metal technology, which has no market equivalent. We also presented Bactiguard data on the durability of the coating. The relevance of all this data extends beyond the trauma implant and our Zimmer Biomet relationship, and is something we can leverage for the technology across all of our partnerships. Also during the quarter, an independent study from the University of Bari Aldo Moro in Italy was published. These results further confirmed promising infection prevention outcomes with the ZNN Bactiguard nail in high-risk fracture patients. The combination of a differentiated mechanism, demonstrated durability, and good clinical outcomes creates trust in the Bactiguard noble metal technology, both from clinicians and hospitals deciding which trauma nail products to purchase, but also for potential new partners. Now let's turn to business development. This slide is a snapshot across the therapeutic areas and the various categories of our partnerships, including material transfer agreements, application development, exclusivity, and license partnerships. Given the expected lead times associated with partnership and product development in medtech, we continue to take a long-term perspective on these opportunities. Having said that, during the quarter, we deepened our engagement and made meaningful headway in various dialogues, which further reinforces our optimism for future product development. Orthopedics is where partner engagement is strongest. This reflects the well-recognized need for infection prevention in implant surgery, and for payers who are increasingly focused on the economic burden of infections. We are also increasingly a strategic partner beyond the noble metal technology itself. Over the past two years, we have expanded our regulatory expertise and our direct dialogue with authorities, including the US FDA, to help partners through an efficient product approval process, and we continue to strengthen the scientific evidence behind the technology. That growing involvement shows how the value we bring extends beyond the coating. As always in a licensed business, discussions like these take time to mature into signed agreements, and our focus remains firmly on advancing them. Now let's turn to wound management. After a very strong second quarter, wound management had a softer third quarter. Revenues were 14 MSEK, down just under 9% excluding currency, mainly reflecting product order phasing and the inherent variability from quarter to quarter. The longer-term picture is therefore more relevant, and wound management grew approximately 14% organically over the first nine months, led by Hydrocyn aqua. We continue to invest in ensuring product availability, including the MDR process and our operations in Penang, Malaysia. And as we've said before, we continue to expect double-digit growth from the wound management portfolio. With that, over to Patrick for a closer look at the numbers.

Patrick Bach
07:47 - 14:22

Thank you. Thank you, Christine. I am very happy to dive into the strong financials. In short, we delivered strong revenue growth, flat OPEX, accelerated EBITDA margins, and cash flow generation this quarter, driven by our strong development across our licensed business. For the third quarter, we report a total revenue growth of more than 21% at constant currencies. Total revenue came in at 58.5 MSEK for the quarter and 166.5 MSEK year to date. Now, on a rolling 12-month basis, we see revenues at constant exchange rates close to 240 MSEK. Similarly, net sales grew 24% in the quarter at constant currencies, driven by our license business and delivering solid growth as well. On a year-to-date basis, we reported more than 9% growth. Now, looking closer at our core license business, our license revenues accelerated due to strong demand from both partnerships in neurology and orthopaedics. In particular, we see increasing demand from BD, which came in at almost 38 MSEK for the quarter, up more than 30% at constant currencies. Also, on a year-to-date basis, we report more than 9% growth. And right now, we see increasing demand and growth from existing markets, and in particular, from new markets and new market launches across the EU and the Middle East. As Christine mentioned, we see the strongest demand and volumes shipped to BD in a decade. We are pleased to see the increase in coated catheters being used worldwide, and we are equally excited about the future to come. Zimmer Biomet contributed with a bit more than 3 million MSEK for the quarter, in line with our expectations and reflecting double-digit growth in sales and demand for the ZNN Bactiguard catheter systems across European markets. Across both of our partnerships, we do see continued positive in-market volume and sales growth. In particular, we see the accelerated demand from BD in new markets, but we also see positive demand within Zimmer Biomet trauma and as well across orthopaedics in general. We see clear and accelerated demand for our technology to prevent infections. Now turning to OpEx costs for the quarter and for the year to date period as well. We continue to manage and keep our total operating costs flat. We do this despite continuing to invest in future growth, such as our efforts in regulatory pathways and even in new clinical data and evidence, as Christine mentioned. This truly sets our technology apart. This goes for our licensed business, but also for our wound management business in Malaysia. As we continue to strengthen that platform for continued profitable growth. Now turning to profitability. Driven by strong growth and demand for our licensed business, increasing gross margins, and flat operating expenses, we delivered a strong and profitable quarter. Adjusted EBITDA came in at 20 MSEK for the quarter, up more than 14 MSEK versus Q3 last year and corresponding to a margin of 34%. This represents more than triple our margin from last year. On a year-to-date basis, we now reach more than 30 MSEK in adjusted EBITDA, and our rolling 12-month figure now sits above 55 MSEK, with a margin of 24%. Now, we are pleased to demonstrate this scalability and leverage in our P&L that we see from the growing demand in our license business, and we are equally excited to continue to demonstrate this in the future. For the quarter, we also turned a positive net profit of more than 7 MSEK, an improvement of more than 14 MSEK versus Q3 last year. Turning to cash flow in the quarter, we delivered a strong cash flow from operating activities of 14 MSEK, a substantial improvement of more than 16 MSEK from Q3 last year. Equally, on a year-to-date basis, we see positive cash flow from operating activities of almost 19 MSEK. Also here, this represents a more than 30 MSEK improvement for the nine-month period versus last year. Our total cash flow for the period was also positive at about 10 MSEK for the quarter, and is also positive for the year-to-date period. Now, given the positive cash flow in Q3, our total cash at the end of the quarter increased to 55 million MSEK. With this quarter's continued positive developments in terms of profitability and cash flow, I wanted to highlight the transformation, which is visible when we zoom out and look across periods for both profitability and cash flow. We now stand with a solid, profitable, cash-generating platform. We have lifted our adjusted EBITDA by more than 125 million MSEK since our reported 2023 number, and our business model today allows us to accelerate and scale that further with increased demand in our licensed business. At the same time, we have de-risked the business and lowered our debt and leverage. Again, this is despite investing in future growth and strengthening our organization as needed, both in Sweden and in Malaysia, as this chart demonstrates. We have also reduced our net debt to 64 MSEK, excluding leasing, corresponding to a ratio of about 1.2 times our adjusted EBITDA for the rolling 12 months. With the strong results for Q3, we are pleased to demonstrate the accelerated performance and we're excited about the future ahead. With that, I hand it back to Christine.

Christine Lind
14:30 - 18:02

Thank you, Patrick. Looking ahead, we see good reason for optimism. The progress we've made with BD and Zimmer Biomet strengthens our conviction in the long-term potential of these partnerships. We expect continued acceleration within our licensed business, supported by growing market traction and increasing demand for Bactiguard coated products in our existing partnerships. We will keep supporting our partners through the commercialization journey to accelerate adoption in new markets, while advancing potential partner dialogue to capture the significant long-term opportunities, especially in orthopedics, and deepening our engagement across our prioritized therapeutic areas. Across our ongoing partner dialogues, we see an interest that reinforces our confidence in the opportunities ahead, and our business development efforts remain firmly focused on advancing those discussions towards agreements. We continue to invest in areas that will drive our ability to capture the opportunity created by the intersection of unmet clinical need to reduce infection risk and the cost burden of these infections, both monetary and in lost quality of life. We do this by delivering new data that increases the appreciation of Bactiguard Noble Metal Coating as a technology platform, enabling future product development, and by advancing regulatory programs, facilitating product approvals and market access for partners, including in the US. We continue to work through MDR transition activities for the trauma implant, as well as in the wound management portfolio, to ensure maintained product registrations. Additionally, in wound management, our focus is on growing profitably and expanding into new markets by expanding the reach of Hydrocyn aqua across key markets. Disciplined portfolio optimization and continued investment in our Malaysia operations. We believe the underlying market dynamics, together with that expansion, provide a solid foundation for future profitable growth. Our strategic direction is unchanged, and we remain committed to our 2030 targets. So to sum up, this was a very strong quarter and the growing market traction validates the large potential in our partnership model. Net sales were up 24% excluding currency, driven by license revenue growth of 40%. Our work with BD delivered this partnership's strongest performance in a decade, with demand from both established and recently launched markets, and market-based revenues from Zimmer Biomet are also gaining momentum. Wound management, despite a softer Q3, delivered double-digit growth over the nine-month period and remains on track longer term. The leverage generated by scaling our partnerships resulted in an adjusted EBITDA of 20 million MSEK in the quarter and operating cash flow of 14 million MSEK. We are advancing the building blocks for future partnerships with progress in regulatory programs, scientific evidence, and engagement with potential partners. Taken together, we move into the final quarter of the year with strong momentum and are optimistic about the future ahead. With that, let's open up for questions.

Operator
18:03 - 18:22

If you wish to ask a question, please dial the pound key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the pound key on your telephone keypad. The next question comes from Maria Karlsson from DNB Carnegie. Please go ahead.

Maria Karlsson
18:24 - 18:51

Hi Christine and Patrick. Thanks for taking my questions. First off, congratulations. Strong set of numbers, but I would still like to start with some detailed questions about BD. Could you paint us a bit of a more detailed picture here? How much of the growth came from the newly launched markets versus the ones that you mentioned are long-standing, stable, and established? Do you have any more details to share than just strong demand ahead?

Patrick Bach
18:54 - 19:33

Maria, this is Patrick. Thank you for your question. In short, we have a global agreement with BD. So we supply BD on a global basis. We are not able to exactly split out the growth from existing and new markets. We are not allowed to report that either. What we can see, however, is that we do see positive underlying growth in both existing markets. But, as we report today, growth is also significant from new markets. Obviously, the new markets are growing from a very low base, but we definitely see part of the growth that we see in this quarter coming from the new markets as well.

Christine Lind
19:36 - 20:03

And looking forward, Maria, to your question about whether we can provide more color on the future, we do see BD continuing to launch in new markets, and we support them with various sales training in those regions. I think we have mentioned also trainings that will help them launch in further markets in Asia, as well as continuing to drive demand across Europe. There are still multiple countries available in Europe for BD to continue to launch into, and we expect them to do this.

Maria Karlsson
20:06 - 20:25

All right. And on wound management, then, the slightly softer Q3. Now, because of order phasing as you mentioned. Should we expect a stronger contribution in the coming quarter? And also, I noticed that we haven't talked about continued investment in Malaysia. What does that specifically entail?

Patrick Bach
20:28 - 21:23

Thank you, Maria. That is a good question. So this quarter, obviously, we saw a softer performance on the wound management business, which, as we described, is primarily due to order phasing. We continue to see very strong demand for the Hydrocyn aqua portfolio in the wound management business, and we continue to expect double-digit growth for the full year and for the years ahead. When we talk about investments in Malaysia, we talk about investments within the organization. We also talk about operational investments in machinery. And we also talk about MDR investments. So all these are within our costs today and are held within our OpEx lines, being flat for the quarter and also for the year-to-date period.

Maria Karlsson
21:26 - 21:36

Thank you. Since you are on the last one, a super short one on costs. So for the quarter, it is flattish or a bit down year over year. How should we think about the cost base going forward?

Patrick Bach
21:38 - 22:25

Yes. Thank you. Good question. We have obviously communicated over the past quarters and years that we deliberately have taken costs out of our business to have the scalable platform that we have today. We do not expect to reduce in terms of salary costs. On the contrary, we have said that we are investing in our organization and we will continue to do so as needed. At the same time, we are pulling out savings from other operating costs. So for this quarter and for the year-to-date period, it is flat. We don't expect to keep it necessarily flat or certainly not decreasing going forward. But we will continue to see a very scalable platform also in terms of OpEx going forward.

Maria Karlsson
22:28 - 22:31

All right. Thank you very much. I will go back into the queue.

Christine Lind
22:32 - 22:33

Thank you Maria.

Operator
22:34 - 22:45

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. The next question comes from Matthias from SEB. Please go ahead.

Matthias
22:47 - 23:33

Hi. Thanks for taking my questions and congratulations on a strong year to date. I have a follow-up on the BD side. So I just want to make sure that we cover this discussion around the stocking effect. It has been there in the past. Yes, you have been managing that, and it typically evens out in a few quarters' time. Does this support thinking that there is some positive stocking effect and that we should be careful about Q4 specifically? Yes, I just wanted to make sure that we cover that aspect of it. That is my question.

Patrick Bach
23:33 - 24:37

Yeah. Good question. Matthias. To be honest, we have obviously considered that ourselves, and we have dived into that and we have in-depth discussions with BD. We see a very positive quarter in Q3, lifted by growth in both existing and new markets. When you do launch in new markets, obviously this will reflect in the books for the first time. As we see it significantly for the quarter, we have confirmed with BD that we do not see, and they do not see, any significant stocking effects. So we do not expect a changed momentum or any downward momentum due to this in future periods. As Christine mentioned, we know some of the markets that are launching, but we also expect further markets to launch. We are excited about the future developments with BD. So in short, no, we do not see any stocking effects in Q3.

Matthias
24:40 - 24:49

Perfect. Is it possible to comment on how many new markets they have launched in today?

Christine Lind
24:52 - 25:40

Hi, Mathias. Unfortunately, we cannot comment on either the number or the specific new markets and effects there. But again, we are happy to note that there is still significant opportunity in terms of launches. The markets where BD is now beginning to roll out are far from the total number of places where they have market rights. So we do see good opportunity here. And we also have a partner who is exceptionally good at market launches and then also maintaining that traction over a very long period of time. So we do expect BD to continue to deliver, not just in terms of new market launches, but also growth for the markets that they have already launched over the coming quarters and over the longer term.

Matthias
25:45 - 26:00

Thank you. I appreciate that. On wound management. So I am sorry if I missed this during the call. But on the order phasing, did you quantify that in any way?

Patrick Bach
26:04 - 26:56

No, we did not quantify the order phasing as such. And we obviously reported a record high Q2. And for Q3, we see a softer quarter with close to a 10% decline. The underlying demand that we see in our business is just as strong in Q3 as it was in Q2. And as we forecasted at the end of the year. So as Christine mentioned, we are very comfortable with that business. And we expect double-digit growth for the full period and for the periods to come. It is a sort of technical order phasing that has to do both with some of the customers we have, but also due to some regulatory order phasing that we experienced in Q3.

Matthias
26:57 - 27:10

Thanks. And to be clear, the comments regarding double-digit growth refer to the full wound management business, not for Hydrocyn aqua. Correct. Okay.

Patrick Bach
27:10 - 27:37

Correct. That is absolutely our expectation as of the year-to-date period. Now we stand at approximately 14% organic growth for the business. And we do expect to continue that for the full year. And as we talked about earlier in the call, we do expect wound management to come back with a strong quarter going forward.

Matthias
27:40 - 28:20

Perfect. That is very clear, I think. So thanks for that. The final question, I just wanted to follow up on the earlier question here on costs for a bit. OPEX is stepping down quite a bit. I would say quarter-over-quarter on the OPEX side. So, selling and other external expenses and operating expenses. So my first question is, are those costs somewhat tied to the wound management sales in any way? So when that is lower, do they go down? Or is this just usual seasonal patterns in your view?

Patrick Bach
28:23 - 29:08

Good. Good question. Obviously to some degree, but not significantly. So you can say we manage our OPEX overall strategically. We talked about, we have no plans to take out further costs. Further costs in terms of salary. Quite the opposite. We have invested in and strengthened our organizations both in Sweden and in Malaysia. We continue to find savings and to operate more efficiently in terms of other external costs. And that is why you see a net effect that in this quarter is flat or even better than that. And for the year-to-date period, it is also flat.

Matthias
29:10 - 29:22

Yeah. And then yes, the final one, to be fully clear, there are no non-recurring effects that are causing the lower costs that you want to single out. Really?

Patrick Bach
29:24 - 30:06

Correct. Uh, yeah. Correct. I think in the past we have flagged if we have any significant changes in accruals or if we have any significant fees on the top line, recognition, or certain milestone payments. This quarter is without any material one-offs or non-recurring effects. Mathias. Both on the top line, but also on the bottom line. So I think what we've spoken about regarding the P&L that we see now in Q3 really demonstrates the leverage and the scale that we see in our business, when we meet increasing demand in our license business.

Matthias
30:09 - 30:13

That's perfectly clear. And thanks so much again for taking my questions.

Unknown 1
30:15 - 30:15

Thank you. Mathias.

Operator
30:17 - 30:24

There are no more questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.

Unknown 2
30:26 - 31:14

We do have some questions in the chat and I think there are some questions about the sustainability of growth, which we already have touched upon. We also touched upon the question concerning OPEX and the seasonality of it. But regarding this one, I think we should highlight that royalty revenue is now more closely tied to underlying market performance, with double-digit growth from product sales-based royalties. What fixed or minimum component came out when the agreement was amended? And what is the gross license run rate now versus the old structure? I guess it's a question for you, Patrick.

Patrick Bach
31:14 - 32:34

Yeah. Thank you. As we reported in the quarter, we see double-digit growth from the in-market sales and royalties with Zimmer Biomet. This comes from the ZNN Bactiguard system across Europe. And we are very pleased to see that obviously, as we have discussed, that is still from a low base, relatively at least to the other partnerships we do have. So we are, of course, looking for that to increase and to expand that across more therapeutic areas within orthopedics. As we have also disclosed over the last periods, we have changed our partnership together with Zimmer Biomet. We today have a non-exclusive agreement for the trauma nail system, which covers that, and we do have fixed fees as well as royalties coming from that agreement. Still within the total reported figures. We do have a majority of fixed fees in there. But we do see a growing amount coming from the in-market royalties derived from positive demand and sales growth of the ZNN and Bactiguard nail system.

Unknown 2
32:37 - 32:49

Thank you. And on the cost side, we also have a question on the capitalization. The question is how much development spend was capitalized rather than expensed in the quarter.

Patrick Bach
32:51 - 33:57

Yeah. So, as I think Mathias also asked about, we do not have any sort of particular non-recurring items or any significant capitalization of R&D work or anything. What we have reported in our results is that part of the OPEX costs that we report is taken out of the Adjusted EBITDA. This relates to what we see as non-recurring adjustments for MDR costs. We have that approximately 6 million for the year-to-date period for the nine months. And as previously, we have flagged this for 2026 and 2027. And while this can vary from quarter to quarter, I would say the 6 MSEK for the year-to-date period is a good run rate that we can apply and expect for 2026 and for 2027. Again, this is included in the total OPEX cost, but we exclude it in the adjusted EBITDA figure.

Unknown 2
33:58 - 34:00

Thank you. There are no more questions from the chat.

Christine Lind
34:09 - 34:26

Okay. Then we will say thank you for all of your questions and for your continued interest in Bactiguard and reiterate our optimism for the future ahead. We look forward to seeing you for the next quarter. With that, back to you. Operator.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…